INNATE PHARMA SP.ADR/1 (IDDA) — Defensive Interval Ratio
INNATE PHARMA SP.ADR/1 (IDDA) has a Defensive Interval Ratio of 66 days as of December 2025. Defensive assets of €6.61 Million (cash €-, short-term investments €6.22 Million, receivables €391.00K) cover 66 days of daily cash needs of €100.41K/day. Check tangible equity quality of INNATE PHARMA SP.ADR/1 to evaluate the tangible quality of the company's equity base.
Defensive Interval Ratio
Defensive Assets
Daily Cash Need
Current Liabilities
INNATE PHARMA SP.ADR/1 Defensive Interval Ratio (2021–2025)
This chart shows how INNATE PHARMA SP.ADR/1's Defensive Interval Ratio has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the ratio stands at 66 days, meaning defensive assets of €6.61 Million can fund 66 days of operations without new revenue. Also explore INNATE PHARMA SP.ADR/1 net asset momentum to track the company's year-over-year net asset growth rate.
Annual Defensive Interval Ratio for INNATE PHARMA SP.ADR/1 (2021–2025)
The table below presents the year-by-year Defensive Interval Ratio for INNATE PHARMA SP.ADR/1 from 2021 to 2025, covering 5 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. For live market cap and the full company financial profile, see INNATE PHARMA SP.ADR/1 market capitalisation.
| Year | DIR (days) | Defensive Assets (EUR) | Daily Cash Need | Cash | ST Investments | Change (days) |
|---|---|---|---|---|---|---|
| 2025 | 66 days | €6.61 Million | €100.41K/day | €- | €6.22 Million | ▼ -100 days |
| 2024 | 166 days | €15.02 Million | €90.36K/day | €- | €14.37 Million | ▼ -175 days |
| 2023 | 341 days | €37.08 Million | €108.59K/day | €- | €21.85 Million | ▲ +162 days |
| 2022 | 180 days | €20.34 Million | €113.25K/day | €- | €17.26 Million | ▲ +102 days |
| 2021 | 77 days | €16.93 Million | €218.87K/day | €- | €16.08 Million | — |